Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30124% above fair value
$7.65−0.12 (-1.54%)
Close on Nov 17, 2026Market cap $410.72MP/E –Yield –
Alpha Teknova operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alpha Teknova's operating income for the twelve months ending Jun 30, 2026 was -$15.81M. For fiscal 2025 it was -$16.98M. The highest annual figure on record is $4.66M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.98M | – |
| FY2024 | Dec 31, 2024 | -$26.15M | – |
| FY2023 | Dec 31, 2023 | -$35.56M | – |
| FY2022 | Dec 31, 2022 | -$49.66M | – |
| FY2021 | Dec 31, 2021 | -$12.01M | -357.5% |
| FY2020 | Dec 31, 2020 | $4.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.96M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.43M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.77M | -699.6% |
| Q3 FY2021 | Sep 30, 2021 | -$3.89M | -280.7% |
| Q2 FY2021 | Jun 30, 2021 | -$2.53M | -458.8% |
| Q1 FY2021 | Mar 31, 2021 | -$828.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $795.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $2.15M | – |
| Q2 FY2020 | Jun 30, 2020 | $704.00K | – |
See a number that looks wrong?